Indication
Chronic myelocytic leukemia
Chronic myelocytic leukemia, more commonly designated chronic myeloid or myelogenous leukemia, is an indolent myeloproliferative neoplasm characterized by the clonal expansion of mature and maturing granulocytic cells within the blood and bone marrow. Read more about Chronic myelocytic leukemia
15 drugs 15 manufacturers
Drugs that treat it
Common Chronic myelocytic leukemia therapies.
HYDROXYUREA
HYDROXYUREA
HYDROXYUREA
HYDROXYUREA
HYDREA (hydroxyurea)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonChronic myelocytic leukemia, more commonly designated chronic myeloid or myelogenous leukemia, is an indolent myeloproliferative neoplasm characterized by the clonal expansion of mature and maturing granulocytic cells within the blood and bone marrow.
It predominantly affects adults, with incidence increasing with age, though it can occasionally arise in children.
Pathophysiologically, the condition is defined by the Philadelphia chromosome, a reciprocal translocation between chromosomes 9 and 22 that produces the constitutively active BCR::ABL1 tyrosine kinase fusion gene, driving unregulated cellular proliferation and resistance to apoptosis.
Untreated or advanced disease characteristically progresses from a stable chronic phase through an accelerated phase to an acute, highly aggressive blast crisis.
- cancer.org
Chronic myelocytic leukemia, more commonly designated chronic myeloid or myelogenous leukemia, is an indolent myeloproliferative neoplasm characterized by the clonal expansion of mature and maturing granulocytic cells within the blood and bone marrow It predominantly affects adults, with incidence increasing with age, though it can occasionally arise in children
- nih.gov
Chronic myelocytic leukemia, more commonly designated chronic myeloid or myelogenous leukemia, is an indolent myeloproliferative neoplasm characterized by the clonal expansion of mature and maturing granulocytic cells within the blood and bone marrow Pathophysiologically, the condition is defined by the Philadelphia chromosome, a reciprocal translocation between chromosomes 9 and 22 that produces the constitutively active BCR::ABL1 tyrosine kinase fusion gene, driving unregulated cellular prolif...
- nih.gov
Chronic myelocytic leukemia, more commonly designated chronic myeloid or myelogenous leukemia, is an indolent myeloproliferative neoplasm characterized by the clonal expansion of mature and maturing granulocytic cells within the blood and bone marrow Untreated or advanced disease characteristically progresses from a stable chronic phase through an accelerated phase to an acute, highly aggressive blast crisis
- cancer.gov
It predominantly affects adults, with incidence increasing with age, though it can occasionally arise in children
- nih.gov
It predominantly affects adults, with incidence increasing with age, though it can occasionally arise in children
- pennmedicine.org
Pathophysiologically, the condition is defined by the Philadelphia chromosome, a reciprocal translocation between chromosomes 9 and 22 that produces the constitutively active BCR::ABL1 tyrosine kinase fusion gene, driving unregulated cellular proliferation and resistance to apoptosis
- nih.gov
Pathophysiologically, the condition is defined by the Philadelphia chromosome, a reciprocal translocation between chromosomes 9 and 22 that produces the constitutively active BCR::ABL1 tyrosine kinase fusion gene, driving unregulated cellular proliferation and resistance to apoptosis
Personalize your experience
Follow Chronic myelocytic leukemia and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.